We are developing first-in-class immunotherapies for autoimmune diseases and cancer through precise elimination or modulation of cytotoxic T and NK cells via KLRG1. We believe this strategy will result in therapeutics with reduced toxicity compared to existing therapeutic approaches for T cell modulation.
- In the context of certain autoimmune diseases: KLRG1 is present on highly differentiated cytotoxic T cells that are the key mediators of tissue damage
- ABC008 is an anti-KLRG1 cell depleter which selectively removes pathogenic cytotoxic T cells
- In the context of cancer: KLRG1 is an immune checkpoint receptor expressed predominantly on late-differentiated effector and effector memory cytotoxic CD8+ T and NK cells
- ABC015 is an anti-KLRG1 cell activator which reactivates inhibited cytotoxic T and NK cells
Abcuro’s foundational IP was developed by Dr. Steven A Greenberg and licensed from Brigham and Women’s Hospital.